CYMABAY THERAPEUTICS

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral s... mall molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenateโs dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.
CYMABAY THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
1991-01-01
Address:
Hayward, California, United States
Country:
United States
Website Url:
http://www.cymabay.com
Total Employee:
51+
Status:
Active
Contact:
5102938800
Email Addresses:
[email protected]
Total Funding:
366.51 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Universal Analytics Domain Not Resolving Apache
Similar Organizations
Acer Therapeutics
Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for patients with serious rare diseases.
Bexion Pharmaceuticals
Bexion Pharmaceuticals is a privately-held biotech company focused on the development and commercialization of innovative cures for cancer.
BioMarin Pharmaceutical
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Castle Creek Biosciences
Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
CRISPR Therapeutics
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Athenex
Athenex is a biopharmaceutical company that develops and discovers novel therapies for treating cancer and related conditions.
Lentigen
Lentigen Corporation is engaged in the development and commercialization of gene delivery technologies for human diseases.
Nirogy Therapeutics
Nirogy Therapeutics is focusing on small-molecule drugs that target the solute carrier family of transporter proteins (SLCTs).
PAREXEL
PAREXEL is a biopharmaceutical services company that focuses on the development and commercialization of new medical therapies worldwide.
Bambu Global
Bambu Global focuses on developing and commercializing breakthrough scientific discoveries.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Galectin Therapeutics
Galectin Therapeutics uses galectin science and drug development to create new therapies for fibrotic diseases and cancer.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Receptos
Receptos focuses on the discovery, development and commercialization of various therapeutics for immune disorders.
Revive Therapeutics
Revive Therapeutics is focused on the research, development and commercialization ofnovel therapies and technologies company.
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Synta Pharmaceuticals
Synta Pharmaceuticals is focused on developing and commercializing small molecule drugs to treat cancer and chronic inflammatory diseases.
TargImmune Therapeutics
TargImmune Therapeutics is focused on drug development using novel targeted onco-immunotherapies.
ULURU
ULURU engages in the research, development, and commercialization of wound care and mucoadhesive film products.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Abingworth
Abingworth investment in Post-IPO Debt - CymaBay Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - CymaBay Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - CymaBay Therapeutics
Merlin Biomed
Merlin Biomed investment in Series E - CymaBay Therapeutics
Birchmere Ventures
Birchmere Ventures investment in Series E - CymaBay Therapeutics
Alta Partners
Alta Partners investment in Series E - CymaBay Therapeutics
KBC
KBC investment in Series E - CymaBay Therapeutics
Bay City Capital
Bay City Capital investment in Series E - CymaBay Therapeutics
Next Chapter Holdings
Next Chapter Holdings investment in Series E - CymaBay Therapeutics
Versant Ventures
Versant Ventures investment in Series E - CymaBay Therapeutics
Official Site Inspections
http://www.cymabay.com Semrush global rank: 3.02 M Semrush visits lastest month: 5.37 K
- Host name: 40.70.27.35
- IP address: 40.70.27.35
- Location: Boydton United States
- Latitude: 36.6534
- Longitude: -78.375
- Metro Code: 560
- Timezone: America/New_York
- Postal: 23917

More informations about "CymaBay Therapeutics"
CymaBay Therapeutics - Crunchbase Company Profile & Funding
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new โฆSee details»
Gilead Sciences Announces Completion of Acquisition of CymaBay
Mar 22, 2024 โThe acquisition of CymaBay brings us a potential best in disease therapy that could transform the treatment landscape for people with primary biliary cholangitis,โ said โฆSee details»
Gilead Sciences Expands Liver Portfolio With Acquisition of โฆ
Feb 12, 2024 About CymaBay Therapeutics CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other โฆSee details»
CymaBay Therapeutics - AnnualReports.com
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet โฆSee details»
CymaBay Therapeutics 2025 Company Profile: โฆ
Information on acquisition, funding, cap tables, investors, and executives for CymaBay Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
CymaBay Therapeutics - Contacts, Employees, Board Members, โฆ
CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases.See details»
CymaBay Therapeutics IncExecutive & Employee Information
The following section provides information on CymaBay Therapeutics Incโs senior management, executives, CEO and key decision makers and their roles in the organization. For more insight โฆSee details»
CymaBay Therapeutics Inc - Company Profile - GlobalData
CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, liver and other โฆSee details»
CymaBay Therapeutics, Inc.
Explore CymaBay Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 22 clinical trials, 162 news, and 8 literature, Technology Platform ...See details»
CymaBay Therapeutics is focused on the development and ...
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new โฆSee details»
CymaBay Therapeutics - Overview, News & Similar companies
May 18, 2024 View CymaBay Therapeutics (www.cymabay.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as โฆSee details»
CymaBay Therapeutics Company Profile - Craft
Mar 25, 2024 CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare โฆSee details»
CymaBay Therapeutics Inc Locations - GlobalData
Save hours of research time with a comprehensive Sales Intelligence Solution. Understand how CymaBay Therapeutics Inc fits into your total addressable market and Ideal Customer Profile. โฆSee details»
CYMABAY THERAPEUTICS, INC. - reports.quarterlytics.com
These statements reflect the current views of CymaBay Therapeutics, Inc. (โCymaBayโ, the โCompanyโ, โweโ or โusโ) with respect to future events and are based on assumptions and โฆSee details»
PowerPoint Presentation
CymaBay will continue to leverage its expertise in fibrotic, inflammatory and metabolic diseases to develop therapeutics for rare, high unmet need indications *Seladelpar is an investigational โฆSee details»
CymaBay Therapeutics - Funding, Financials, Valuation & Investors
CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases.See details»
How CymaBay Survived a Safety Scare - TimmermanReport.com
At the time, CymaBay was running the key clinical trials to determine the safety and efficacy of its PPAR-delta agonist, seladelpar, for two liver conditions: primary biliary cirrhosis (PBC) and โฆSee details»
CymaBay Therapeutics, Inc. (CymaBay Therapeutics, Inc.) - ่ฏ็ฉ็ฎก โฆ
The company has also licensed a number of drugs from other companies, including seladelpar for primary biliary cholangitis from CymaBay Therapeutics and tildacerfont from Spruce โฆSee details»
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
Feb 12, 2024 Gilead Sciences is buying CymaBay Therapeutics for $4.3 billion, giving Gilead access to CymaBay's lead treatment for liver disease.See details»
CymaBay Therapeutics - Facebook
Jul 30, 2024 CymaBay Therapeutics. 162 likes. We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with โฆSee details»